版本:
中国

REFILE-BRIEF-Ariad Pharma's Brigatinib's safety profile similar with longer follow-up

(Adds dropped words "says Brigatinib's" in headline)

Oct 10 Ariad Pharmaceuticals Inc

* Press release - Ariad presents updated long-term follow-up results from the phase 1/2 trial on investigational drug Brigatinib at 2016 ESMO meeting

* Ariad Pharmaceuticals Inc - safety profile was similar with longer follow-up

* Ariad Pharmaceuticals Inc - in eight Crizotinib-Naive ALK+ NSCLC patients, confirmed ORR was 100% Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐